Saladax Biomedical, Inc. Appoints Li Zhang, M.D., to Scientific Advisory Board — (Read More)

Saladax Biomedical, Inc. Names Edward Chu, M.D., Chair of the Company’s Scientific Advisory Board — (Read More)

Bristol-Myers Squibb and Saladax Biomedical Expand Collaboration for Diagnostic Assays for Alzheimer’s Disease — (Read More)

Saladax Biomedical, Inc. to Present at the Annual UBS Global Life Sciences Conference in New York City — (Read More)

Saladax Biomedical, Inc. Enters Agreement with Kaan Medikal for Distribution of My5-FU in Turkey — (Read More)

Saladax Biomedical, Inc. Announces Appointment of Gregory C. Critchfield, M.D., M.S. as Chairman of the Company’s Board of Directors — (Read More)

Saladax Biomedical, Inc. Completes $9 Million Debt Financing with GE Capital — (Read More)

Saladax Biomedical, Inc. Announces Inclusion of My5-FU in Australian Register of Therapeutic Goods (ARTG) — (Read More)

Saladax Biomedical, Inc. Announces Pacific Rim Commercialization Team in Australia and China — (Read More)

Saladax Biomedical, Inc. Announces European Commercialization Team — (Read More)

Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Small Cell Lung Cancer — (Read More)

Saladax Biomedical Appoints Edward L. Erickson as President and CEO — New CEO to Lead Company to Commercializing Personalized Medicine Products — (Read More)

Saladax Biomedical Adds Industry Expert to Board of Directors — Gregory Critchfield, Formerly of Myriad Genetic Laboratories, Inc., Brings Broad Experience in Innovative Diagnostics — (Read More)

Saladax Biomedical Achieves ISO Certification for Design, Manufacture and Distribution of In Vitro Diagnostics — (Read More)

Saladax Biomedical Signs Deal with Bristol-Myers Squibb to Develop Clinical Diagnostics — (Read More)

Saladax Biomedical Expands Executive Team with New Vice President of Clinical Development and Regulatory Affairs — Gary Lee Feiss Joins Saladax to Lead Clinical Development for MYCARE” Portfolio of Personalized Medicine Assays — (Read More)

Saladax Biomedical Executes Exclusive Distribution Agreement with FALCO SD for the 5-FU MYCARE Assay in Japan –Test May Prevent Reduced Efficacy or Excess Side Effects Through Accurate Dosing of 5-Fluorouracil — (Read More)

Saladax Biomedical Closes $8 Million Series C Financing. Accelerates Development of Personalized Patient Dosing For Cancer and CNS Disorders — (Read More)

Saladax Biomedical, Inc. Signs Agreement With Stockholm’s Karolinska University Hospital — (Read More)

Saladax Biomedical Receives Product Innovation Award. Personalized Chemotherapy Management® Tests Are Filling an Unmet Need — (Read More)

License From Saladax Biomedical is Foundation of New Molecular Oncology Test Launched My Myriad Genetics — (Read More)

Saladax Biomedical Receives Innovation Award from Ben Franklin Technology Partners iExchange…. — (Read More)

Saladax Biomedical 5-FU PCM® Immunoassay for Chemotherapy Treatment Individualization Promises Multiple Benefits in Treatment of Colorectal Cancer — (Read More)

Saladax Biomedical Enters Agreement With Karolinska University Hospital In Sweden To Supply 5-Fu Personalized Chemotherapy Management Assay — (Read More)

New Data Demonstrates 5-FU Personalized Chemotherapy Management (PCM”) Assay Provides Similar Performance to More Complicated Liquid Chromatography-Mass Spectrometry (LC-MS/MS) — (Read More)

Saladax Biomedical 5-FU Personalized Chemotherapy Management (PCM”) Assay CE Marked for Distribution in the EU — (Read More)

Studies Point to Benefits of Personalized Chemotherapy Dose Management in Colorectal Cancer — (Read More)

Novel 5-Fluorouracil Immunoassay Proves to Be An Effective Tool for Monitoring 5-FU Blood Concentrations — (Read More)

Delaware Crossing Investor Group Makes a $260,000 Investment in Saladax Biomedical, Inc. — (Read More)

New York State Health Department Approves Busulfan Testing by Memorial Sloan-Kettering Cancer Center — (Read More)

Saladax Biomedical Launches First Analyte Specific Reagent* (ASR) for Determination of Busulfan Blood Concentrations. — (Read More)

Saladax Biomedical to Present at Leading Life Science Conferences in 2007 — (Read More)

Olympus, in Cooperation With Saladax Biomedical, Prepares to Offer Testing in Support of Personalized Chemotherapy — (Read More)

ARUP Laboratories and Saladax Biomedical Sign Agreement for Busulfan Analyte Specific Reagents — (Read More)

Novel Monoclonal Antibodies to Measure Levels of 5-Fluorouracil in Plasma — (Read More)

Monoclonal Antibodies to Help Oncologists Measure Chemotherapy Levels in Plasma — (Read More)